We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint | Next Generation Neurology

Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis Is Intrathecal Anti-CD20 a Therapeutic Option?

Mahboobeh Fereidan-Esfahani1,2; Wolfgang Brück, MD1; Martin S. Weber, MD1,3
[+] Author Affiliations
1Institute of Neuropathology, University Medical Centre, Göttingen, Germany
2Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Science, Isfahan, Iran
3Department of Neurology, University Medical Centre, Göttingen, Germany
JAMA Neurol. 2015;72(12):1407-1408. doi:10.1001/jamaneurol.2015.2869.
Text Size: A A A
Published online


This Viewpoint discusses the potential of B cells and B cell–derived products in chronic progression of multiple sclerosis.

Multiple sclerosis (MS) is an immune-mediated chronic disease of the central nervous system (CNS). In most patients, MS starts with a relapsing-remitting (RR) disease course followed by a secondary progressive (SP) phase with slowly accumulating disability, often in the absence of acute exacerbations. Few patients develop a primary progressive (PP) disease course with no circumscribable relapses from the very beginning. A recently proposed new classification of the clinical course of MS puts active and progressive disease as the 2 main phenotypes in the focus. While the pathophysiological correlate of relapses is assumed to be a concerted infiltration by systemic leukocytes resulting in a magnetic resonance imaging–detectable focal inflammatory CNS white matter lesion, the mechanisms behind the slowly progressing aspect of MS are not well understood. Emerging evidence suggests that, besides focal white matter lesions, widespread diffuse inflammation throughout otherwise “normal-appearing” white matter and involvement of the gray matter could be the major cause of tissue loss in MS brains and by that be the main correlate of gradually declining cognitive and motor function. Most importantly, this CNS-intrinsic inflammation is believed to be sustained by positive feedback loops between CNS resident cells, such as astrocytes and microglia and CNS-established leukocytes, and accordingly, disease progression may therefore no longer depend on de novo CNS infiltration by peripheral leukocytes; this likely scenario could explain why all current MS agents primarily targeting function or migration of peripheral immune cells essentially failed to halt progression in progressive MS.1

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles